NovoCure News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

13.05.20	China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma (Businesswire)
30.04.20	Novocure Reports First Quarter 2020 Financial Results and Provides Company Update (Businesswire)
03.04.20	Novocure Provides Business Update Related to COVID-19 (Businesswire)
27.03.20	Gemeinsamer Bundesausschuss beschliesst Aufnahme von TTFields in die Richtlinie Methoden Vertragsärztlicher Versorgung (MVV-RL) (Businesswire)
20.03.20	German Federal Joint Committee Updates Medical Care Directive to include Tumor Treating Fields, establishing National Reimbursement for Optune in Germany (Businesswire)
19.03.20	Novocure Announces Optune Lua™ as the Brand Name for the NovoTTF-100L™ System (Businesswire)
12.03.20	Preclinical Data Show Tumor Treating Fields Induces Immunogenic Cell Death Resulting in Enhanced Antitumor Efficacy When Combined with Anti-PD-1 Therapy (Businesswire)
27.02.20	Novocure Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Company Update (Businesswire)
21.01.20	Novocure Announces National Reimbursement in Israel for Optune® in Combination with Temozolomide for the Treatment of Newly Diagnosed Glioblastoma (Businesswire)
13.01.20	Novocure Announces Fourth Quarter and Full Year 2019 Preliminary Net Revenues and Provides Company Update (Businesswire)
09.01.20	Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer (Businesswire)
26.12.19	Novocure to Participate in the 38th Annual J.P. Morgan Healthcare Conference (Businesswire)
02.12.19	Novocure and the AACR Announce 2nd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program (Businesswire)
26.11.19	Novocure to Participate in the Evercore ISI 2019 HealthCONx Conference (Businesswire)
20.11.19	Novocure Announces 43 Presentations on Tumor Treating Fields at 24th Annual Meeting of the Society for Neuro-Oncology (Businesswire)
31.10.19	Novocure Reports Third Quarter 2019 Financial Results and Provides Company Update (Businesswire)
16.10.19	Results from STELLAR Trial of Tumor Treating Fields with Chemotherapy in Malignant Pleural Mesothelioma Published in The Lancet Oncology (Businesswire)
01.10.19	Novocure to Report Third Quarter 2019 Financial Results (Businesswire)
09.09.19	Novocure Announces 27 Presentations at the American Society for Radiation Oncology 2019 Annual Meeting (Businesswire)
16.08.19	Can NovoCure Hit $100? (RTTNews)
12.08.19	China National Medical Products Administration Grants Innovative Medical Device Designation for Optune® in China (Businesswire)
06.08.19	Novocure to Participate in Three Upcoming Investor Conferences (Businesswire)
25.07.19	Novocure Reports Second Quarter 2019 Financial Results and Provides Company Update (Businesswire)
22.07.19	Novocure Announces 10 Oral Presentations and a Special Session on Tumor Treating Fields at the 41st International Engineering in Medicine and Biology Conference (Businesswire)
19.07.19	CMS Establishes 2019 Monthly Fee Schedule Amount for Optune® (Businesswire)
18.07.19	Medicare Releases Final Local Coverage Determination Providing Coverage of Optune® for Newly Diagnosed Glioblastoma (Businesswire)
02.07.19	Novocure to Report Second Quarter 2019 Financial Results (Businesswire)
26.06.19	German Institute for Quality and Efficiency in Healthcare Publishes Rapid Report Noting Optune’s Survival Benefit for Patients with Newly Diagnosed Glioblastoma (Businesswire)
24.05.19	Novocure to Participate in the Jefferies 2019 Global Healthcare Conference (Businesswire)
23.05.19	FDA Approves the NovoTTF-100LTM System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma (Businesswire)
14.05.19	Novocure mit 13 Präsentationen und einem Symposium zu Tumortherapiefeldern auf der 70. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie vertreten (Businesswire)
14.05.19	Novocure Announces 13 Presentations and a Symposium on Tumor Treating Fields at the 70th Annual Meeting of the German Society of Neurosurgery (Businesswire)
10.05.19	Medicare Issues Proposed Local Coverage Determination that Provides Coverage of Optune® for Newly Diagnosed Glioblastoma (Businesswire)
02.05.19	Novocure Reports First Quarter 2019 Financial Results and Provides Company Update (Businesswire)
15.04.19	Novocure Publishes 2018 Annual Report Featuring Company’s Vision, Mission and Values (Businesswire)
03.04.19	Inaugural AACR-Novocure Tumor Treating Fields Research Grant Recipients Announced at AACR Annual Meeting 2019 (Businesswire)
02.04.19	Novocure to Report First Quarter 2019 Financial Results (Businesswire)
22.03.19	Novocure Initiates Phase 3 Pivotal Trial in Recurrent Ovarian Cancer (Businesswire)
21.03.19	Novocure Announces 48 Presentations and a Symposium Session on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2019 (Businesswire)
21.03.19	Novocure’s Chief Science Officer Retires after 17 Years of Service (Businesswire)
18.03.19	Novocure to Participate in Oppenheimer’s 29th Annual Healthcare Conference (Businesswire)
28.02.19	Novocure Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update (Businesswire)
07.01.19	Novocure Announces Fourth Quarter and Full Year 2018 Operating Statistics, Preliminary Net Revenues and Provides Company Update (Businesswire)
21.12.18	Novocure to Participate in the 37th Annual J.P. Morgan Healthcare Conference (Businesswire)
17.12.18	Novocure and the AACR Announce Four Inaugural Research Grants to Promote and Support Innovative Research on Tumor Treating Fields (Businesswire)
06.12.18	Sub-Group Analysis of Novocure’s EF-14 Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Published in Journal of Neuro-Oncology Demonstrating More Time on Optune® Predicted Increased Survival (Businesswire)
14.11.18	Novocure and Zai Lab Awarded Deal of the Year at 5th Annual BioCentury China Healthcare Summit in Shanghai, China (Businesswire)
13.11.18	Novocure Announces More than 70 Presentations on Tumor Treating Fields at 23rd Annual Meeting of the Society for Neuro-Oncology (Businesswire)
07.11.18	Novocure and Zai Lab to Host Investor Event (Businesswire)
26.10.18	ALGN Plunges, NVCR's Q3 Revenue Lags Estimate, SELB Continues To Bleed (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Swiss Re	133.55	4.50 %	K V
Kuehne+Nagel Int	207.00	0.98 %	K V
Swiss Life Hldg	693.60	0.93 %	K V
Zurich Insur Gr	552.60	0.88 %	K V
Sonova Hldg	294.70	0.82 %	K V
Sika	227.80	-1.21 %	K V
Alcon	75.42	-1.49 %	K V
Geberit	538.60	-1.54 %	K V
Part Grp Hldg	1’264.00	-1.60 %	K V
Lonza Grp	535.20	-2.37 %	K V

Nachrichten zu NovoCure Limited

Aktien Top/Flop

Meistgelesene Nachrichten